DrugPatentWatch

Search for Tradename: CYMBALTA

Summary for Tradename: CYMBALTA

Patents:3
Applicants:1
NDAs:1
2009 Sales:$2,404,353,000
Therapeutic Class:Antidepressants
Glossary
Applicant Tradename Generic Name NDA Approval Date Type RLD Patent Number Product Substance Delist Req. Patent Expiration Exclusivity Expiration
LillyCYMBALTAduloxetine hydrochloride021427Aug 3, 2004RXNoAug 3, 2009
LillyCYMBALTAduloxetine hydrochloride021427Aug 3, 2004RXNoFeb 23, 2010
LillyCYMBALTAduloxetine hydrochloride021427Aug 3, 2004RXNoJun 13, 2011
Export available with Ultimate Plan subscription: 

This preview shows a limited data set. Complete access is available with a Subscription

 

Paragraph IV activity for: CYMBALTA

Drugname Dosage Strength RLD Submissiondate
duloxetine hydrochlorideDelayed-release Capsules20 mg, 30 mg and 60 mgCymbalta8/4/2008

<- Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:
 2000  2001  2002  2003  2004 
 2005  2006  2007  2008  2009 


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright © 2000-2010, thinkBiotech LLC.


[ Home | Site Tour | Plan Comparison | Free Patent Expiration Newsletter | Affiliate Program | Contact ]
Drug Patent ExpirationsFollow DrugPatentWatch on Twitter
Bookmark or Share This Page ...
[del.icio.us] [Digg] [Reddit] [Facebook] [LinkedIn] [StumbleUpon] [Technorati] [Twitter] [Email]